期刊文献+

多学科综合治疗助力乳腺癌质量控制规范化

Multidisciplinary team improve the quality control of breast cancer diagnosis and treatment
下载PDF
导出
摘要 医疗资源分配的不均质导致不同医院、不同地区之间乳腺癌的治疗水平参差不齐,因而实施单病种规范诊疗质量控制工作非常重要。而国内外实践已经证明多学科综合治疗模式是确保乳腺癌治疗规范化的重要手段。 The uneven distribution of medical resources leads to the uneven treatment level of breast cancer in different hospitals and regions,so it is very important to implement the quality control of standardized diagnosis and treatment of single disease.Domestic and international practices have proven that the multi-disciplinary treatment model is an important means to ensure the standardization of breast cancer treatment.
作者 乔江华 刘真真 Qiao Jianghua;Liu Zhenzhen(Department of Breast Disease,Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital,Zhengzhou 450008,China)
出处 《肿瘤综合治疗电子杂志》 2023年第3期19-22,共4页 Journal of Multidisciplinary Cancer Management(Electronic Version)
基金 河南省卫生健康创新人才-领军人才项目(YXKC2022005)。
关键词 乳腺癌 多学科综合治疗 质量控制 Breast cancer Multi-disciplinary treatment Quality control
  • 相关文献

参考文献9

二级参考文献90

  • 1贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:73
  • 2吴孟超,吴在德.黄家驷外科学[M].7版,北京:人民卫生出版社,2008:1329-1330.
  • 3Li J,Gong FJ,Shen L,et al.Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumour[J].Euro J Sur Oncol,2011,37(4):319-324.
  • 4Corless CL,Ballman KV,Antonescu C,et al.Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST):Results of the intergroup phase Ⅲ trial ACOSOG Z9001[J].J Clin Oncol,2010,28 (15 Suppl):a10006.
  • 5Joensuu H,Eriksson M,Hartmann J,et al.Twelve vs 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence:final results of a randomized trial (SSGXⅧ/AIO)[J].J Clin Oncol,2011,29(Suppl):aLBAI.
  • 6DeMatteo RP,Owzar K,Antonescu CR,et al.Efficacy of adjuvant imatinib mesylate following complete resection of localized,primary gastrointestinal stromal tumor (GIST) at high risk of recurrence:The U.S.Intergroup phase Ⅱ trial ACOSOG Z9000[C/OL].2011[2011-07-29].http://www.anco.org/ascov2/Meetings/Abstracts? &vmview = abst-detail-view&confID =53&abstractID = 10450.
  • 7Demetri GD,von Meherm M,Blanke CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J].N Engl J Med,2002,347(7):472-480.
  • 8Zalcberg JR,Verweij J,Casali PG,et al.Outcome of patients with advanced gastrointestinal stromal tumours croasing over to a daily imatinib dose of 800 mg after progression on 400 mg[J].Eur J Cancer,2005,41 (12):1751-1757.
  • 9Rios M,Lecesne A,Bui B,et al.Interruption of imatinib (IM)in GIST patients with advanced disease after one year of treatment:Updated results of the prospective French Sarcoma Group randomized phase Ⅲ trial on long term survival[J].J Clin Oncol,2007,25(18 Suppl):10016.
  • 10Raut CP,Posner M,Dessi J,et al,Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors[J].J Clin Oncol,2006,24(15):2325-2331.

共引文献378

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部